Atossa Genetics Announces Corporate Name Change to Atossa Therapeutics, Inc.
January 06 2020 - 8:00AM
Atossa Therapeutics, Inc. (NASDAQ:
ATOS), a
clinical-stage biopharmaceutical company developing novel
therapeutics and delivery methods for breast cancer and other
breast conditions, today announced that its corporate name change
from "Atossa Genetics Inc." to "Atossa Therapeutics, Inc." became
effective at 12:01 a.m. ET today, January 6, 2020. The Company's
common stock will continue to trade on the NasdaqCM exchange under
the ticker symbol "ATOS."
"Over the last several years, we have transitioned the Company’s
focus on developing therapies to treat breast cancer, breast
density and other breast conditions," said Steve Quay, Ph.D., M.D.,
president and CEO of Atossa. "Changing our name to Atossa
Therapeutics, Inc. more clearly reflects our focus on developing
therapies and continues to honor Princess Atossa, the great queen
of the Achaemenid Empire, who reigned in the fifth century BCE and
who is the earliest recorded woman with breast cancer. She is
featured in the The Emperor of All Maladies: A Biography of Cancer,
the Pulitzer Prize-winning book by Siddhartha Mukherjee on the
history of cancer.”
About Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical
company developing novel therapeutics and delivery methods to treat
breast cancer and other breast conditions. For more information,
please visit www.atossatherapeutics.com.
Forward-Looking Statements
Forward-looking statements in this press release, which Atossa
undertakes no obligation to update, are subject to risks and
uncertainties that may cause actual results to differ materially
from the anticipated or estimated future results, including the
risks and uncertainties associated with any variation between
preliminary and final clinical results, actions and inactions by
the FDA, the outcome or timing of regulatory approvals needed by
Atossa including those needed to commence studies, lower than
anticipated rate of patient enrollment, estimated market size of
drugs under development, the safety and efficacy of Atossa's
products and services, performance of clinical research
organizations and investigators, obstacles resulting from
proprietary rights held by others with respect to fulvestrant, such
as patent rights, potential market sizes for Atossa's drugs under
development and other risks detailed from time to time in Atossa's
filings with the Securities and Exchange Commission, including
without limitation its periodic reports on Form 10-K and 10-Q, each
as amended and supplemented from time to time.
Atossa Company Contact
Atossa Therapeutics, Inc.Kyle GuseCFO and General CounselOffice:
800-351-3902kyle.guse@atossainc.com
Investor Relations Contact:
Scott GordonCoreIR377 Oak StreetConcourse 2Garden City, NY
11530Office: 516.222.2560scottg@CoreIR.com
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Apr 2023 to Apr 2024